Fulvestrant
Examples
Fulvestrant is available as an intramuscular (IM) injection.
How It Works
Fulvestrant is called an antiestrogen medicine. This means that it
blocks the effect of estrogen in the body. It is only used for postmenopausal
women who have been diagnosed with
estrogen receptor-positive (ER+) breast
cancer.
Why It Is Used
Fulvestrant is used to treat estrogen receptor-positive (ER+)
metastatic breast cancer in postmenopausal women when other hormonal therapies,
such as tamoxifen, have stopped working.
How Well It Works
Fulvestrant is as effective as aromatase inhibitors, such as
anastrozole (Arimidex), in the treatment of women for metastatic breast cancer
when other hormonal therapies, such as tamoxifen, have stopped working.1 It only works for postmenopausal women who have been
diagnosed with estrogen receptor-positive (ER+) breast cancer.
Side Effects
Most women do not have problems with side effects while taking
fulvestrant. When side effects happen, they are typically mild and may
include:
- Nausea or vomiting.
- Constipation or
diarrhea.
- Abdominal (belly) pain.
- Headache.
- Back
pain.
- Hot flashes.
- Sore throat.
See Drug Reference for a full list of side effects. (Drug Reference
is not available in all systems.)
What To Think About
Fulvestrant should be given only under the supervision of a
medical oncologist. It is approved for use after
menopause.
Do not take this medicine if you are or may be pregnant. Do not
breast-feed while you are taking this medicine.
Complete the new medication information form (PDF)(What is a PDF document?) to help you understand this medication.
References
Citations
-
Abramowicz M (2005). Drugs for breast cancer.
Treatment Guidelines From The Medical Letter, 3(29):
1–6.
Credits
|
By
|
Healthwise Staff |
|
Primary Medical Reviewer
|
Sarah Marshall, MD - Family Medicine |
|
Specialist Medical Reviewer
|
Douglas A. Stewart, MD - Medical Oncology |
|
Last Revised
|
August 11, 2011 |
Last Revised:
August 11, 2011
Abramowicz M (2005). Drugs for breast cancer.
Treatment Guidelines From The Medical Letter, 3(29):
1–6.